|
[1]A. Fogliata, S. Bergström, I. Cafaro et al., "Cranio-spinal irradiation with volumetric modulated arc therapy: a multi-institutional treatment experience," Radiotherapy and Oncology, vol. 99, no. 1, pp. 79-85, 2011. [2]L. Y. Luo, K. Kramer, N. K. V. Cheung et al., "Reduced‐dose craniospinal irradiation for central nervous system relapsed neuroblastoma," Pediatric Blood & Cancer, vol. 67, no. 9, p. e28364, 2020. [3]S. Suster, C. A. Moran, and D. C. Rice, "6 MEDIASTINUM," Intraoperative Consultation in Surgical Pathology, p. 77, 2010. [4]D. S. Chang, F. D. Lasley, I. J. Das et al., "Normal tissue radiation responses," in Basic Radiotherapy Physics and Biology: Springer, 2014, pp. 265-275. [5]E. Traneus, N. Bizzocchi, F. Fellin et al., "Universal field matching in craniospinal irradiation by a background‐dose gradient‐optimized method," Journal of applied clinical medical physics, vol. 19, no. 1, pp. 46-49, 2018. [6]A. Strojnik, I. Méndez, and P. Peterlin, "Reducing the dosimetric impact of positional errors in field junctions for craniospinal irradiation using VMAT," Reports of Practical Oncology & Radiotherapy, vol. 21, no. 3, pp. 232-239, 2016. [7]E. S. Ho, S. A. Barrett, and L. M. Mullaney, "A review of dosimetric and toxicity modeling of proton versus photon craniospinal irradiation for pediatrics medulloblastoma," Acta Oncologica, vol. 56, no. 8, pp. 1031-1042, 2017. [8]J. Seppälä, J. Kulmala, P. Lindholm et al., "A method to improve target dose homogeneity of craniospinal irradiation using dynamic split field IMRT," Radiotherapy and Oncology, vol. 96, no. 2, pp. 209-215, 2010. [9]J. Lof, B. K. Lind, and A. Brahme, "Optimal radiation beam profiles considering the stochastic process of patient positioning in fractionated radiation therapy," Inverse Problems, vol. 11, no. 6, p. 1189, 1995. [10]J. Löf, B. K. Lind, and A. Brahme, "An adaptive control algorithm for optimization of intensity modulated radiotherapy considering uncertainties in beam profiles, patient set-up and internal organ motion," Physics in Medicine & Biology, vol. 43, no. 6, p. 1605, 1998. [11]D. Pflugfelder, J. Wilkens, and U. Oelfke, "Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy," Physics in Medicine & Biology, vol. 53, no. 6, p. 1689, 2008. [12]R. A. Kleinerman, "Cancer risks following diagnostic and therapeutic radiation exposure in children," Pediatric radiology, vol. 36, no. 2, pp. 121-125, 2006. [13]M. Massimino, M. P. Sunyach, F. Barretta et al., "Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients," Journal of Neuro-Oncology, vol. 148, no. 3, pp. 619-628, 2020. [14]G. T. Armstrong, Q. Liu, Y. Yasui et al., "Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study," Journal of Clinical Oncology, vol. 27, no. 14, p. 2328, 2009. [15]N. R. Council, "Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2," 2006. [16]U. Schneider, M. Sumila, and J. Robotka, "Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy," Theoretical Biology and Medical Modelling, vol. 8, no. 1, pp. 1-21, 2011. [17]N. Lee, J. Harris, A. S. Garden et al., "Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225," Journal of clinical oncology, vol. 27, no. 22, p. 3684, 2009. [18]R. Lilenbaum, R. Komaki, and M. K. Martel, "RADIATION THERAPY ONCOLOGY GROUP RTOG 0623 A PHASE II TRIAL OF COMBINED MODALITY THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER." [19]N. Y. Lee, Q. Zhang, D. G. Pfister et al., "Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial," The lancet oncology, vol. 13, no. 2, pp. 172-180, 2012. [20]H. Lin, X. Ding, M. Kirk et al., "Supine craniospinal irradiation using a proton pencil beam scanning technique without match line changes for field junctions," International Journal of Radiation Oncology* Biology* Physics, vol. 90, no. 1, pp. 71-78, 2014. [21]S. Webb, "The physical basis of IMRT and inverse planning," The British journal of radiology, vol. 76, no. 910, pp. 678-689, 2003. [22]李曉飛, "應用傾向分數配對探討強度調控放射治療和動態弧形強度調控放射治療誘發二次癌症之風險評估:針對鼻咽癌和乳癌病患接受治療為例," 國立高雄科技大學 電子工程系 研究所學位論文, 2018. [23]H. Paganetti, "Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer," Physics in Medicine & Biology, vol. 59, no. 22, p. R419, 2014. [24]Y.-S. Lin, T.-C. Chao, J.-H. Hong et al., "Comparisons of longitudinal and lateral dose profiles and relative biological effectiveness for DNA double strand breaks among 1H, 4He and 12C beams," Radiation Physics and Chemistry, vol. 137, pp. 169-172, 2017. [25]A. Fredriksson, A. Forsgren, and B. Hårdemark, "Minimax optimization for handling range and setup uncertainties in proton therapy," Medical physics, vol. 38, no. 3, pp. 1672-1684, 2011. [26]D. Petrova, S. Smickovska, and E. Lazarevska, "Conformity index and homogeneity index of the postoperative whole breast radiotherapy," Open access Macedonian journal of medical sciences, vol. 5, no. 6, p. 736, 2017. [27]J. Rosenwald, G. Gaboriaud, and D. Pontvert, "Conformal radiotherapy: Principles and classification," Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique, vol. 3, no. 5, pp. 367-377, 1999. [28]S. Ansari, M. K. Zope, and N. Yadav, "A new method for risk factor assessment of organs at risk including conformity index in radiotherapy treatment plan," Journal of Radiotherapy in Practice, vol. 20, no. 2, pp. 144-152, 2021. [29]T. Kataria, K. Sharma, V. Subramani et al., "Homogeneity Index: An objective tool for assessment of conformal radiation treatments," Journal of medical physics/Association of Medical Physicists of India, vol. 37, no. 4, p. 207, 2012. [30]D. Maes, J. Saini, J. Zeng et al., "Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer," Translational lung cancer research, vol. 7, no. 2, p. 114, 2018. [31]A. Wambersie, "ICRU report 62, prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50)," ICRU News, 1999. [32]L. B. Marks, E. D. Yorke, A. Jackson et al., "Use of normal tissue complication probability models in the clinic," International Journal of Radiation Oncology* Biology* Physics, vol. 76, no. 3, pp. S10-S19, 2010. [33]L. B. Marks, "The impact of organ structure on radiation response," International Journal of Radiation Oncology* Biology* Physics, vol. 34, no. 5, pp. 1165-1171, 1996. [34]H. R. Withers, J. M. Taylor, and B. Maciejewski, "Treatment volume and tissue tolerance," International Journal of Radiation Oncology* Biology* Physics, vol. 14, no. 4, pp. 751-759, 1988. [35]D. L. Preston, D. A. Pierce, Y. Shimizu et al., "Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates," Radiation research, vol. 162, no. 4, pp. 377-389, 2004. [36]K. Rycaj and D. G. Tang, "Cancer stem cells and radioresistance," International journal of radiation biology, vol. 90, no. 8, pp. 615-621, 2014. [37]吳俊寬, "顱內腫瘤使用電腦刀之IRIS與InCise MLC放射治療計畫劑量分析與二次癌症風險評估," 國立高雄科技大學 電子工程系 研究所學位論文, 2018. [38]陳昱廷, "肺癌病患接受電腦刀身體立體定位放射治療之二次癌症風險評估," 國立高雄科技大學 電子工程系 研究所學位論文, 2019. [39]陳冠宇, "乳癌病患接受強度調控與動態弧形強度調控放射治療後誘發二次癌症發生率評估:依鎖骨上窩治療狀態分析," 國立高雄科技大學 電子工程系 研究所學位論文, 2017. [40]黃凱俊, "放射治療輻射劑量之誘發二次癌症機率評估與平台建構," 國立高雄科技大學 電子工程系 研究所學位論文, 2016. [41]G. Barendsen, "Dose fractionation, dose rate and iso-effect relationships for normal tissue responses," International Journal of Radiation Oncology* Biology* Physics, vol. 8, no. 11, pp. 1981-1997, 1982. [42]J. F. Fowler, "The linear-quadratic formula and progress in fractionated radiotherapy," The British journal of radiology, vol. 62, no. 740, pp. 679-694, 1989. [43]T. Frometa-Castillo, A. Pyakuryal, A. Wals-Zurita et al., "Biologically Effective Dose (BED) or Radiation Biological Effect (RBEf)?," in Ionizing Radiation Measurement: IntechOpen, 2020. [44]H. Onishi, T. Araki, H. Shirato et al., "Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study," Cancer, vol. 101, no. 7, pp. 1623-1631, 2004. [45]S. P. Lee, M. Y. Leu, J. B. Smathers et al., "Biologically effective dose distribution based on the linear quadratic model and its clinical relevance," International Journal of Radiation Oncology* Biology* Physics, vol. 33, no. 2, pp. 375-389, 1995. [46]U. Schneider, D. Zwahlen, D. Ross et al., "Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose," International Journal of Radiation Oncology* Biology* Physics, vol. 61, no. 5, pp. 1510-1515, 2005. [47]U. Schneider, A. Lomax, J. Besserer et al., "The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer," International Journal of Radiation Oncology* Biology* Physics, vol. 68, no. 3, pp. 892-897, 2007. [48]X. G. Xu, B. Bednarz, and H. Paganetti, "A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction," Physics in Medicine & Biology, vol. 53, no. 13, p. R193, 2008. [49]G. M. Dores, C. Metayer, R. E. Curtis et al., "Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years," Journal of clinical oncology, vol. 20, no. 16, pp. 3484-3494, 2002. [50]D. Preston, E. Ron, S. Tokuoka et al., "Solid cancer incidence in atomic bomb survivors: 1958–1998," Radiation research, vol. 168, no. 1, pp. 1-64, 2007. [51]A. M. Kellerer, E. A. Nekolla, and L. Walsh, "On the conversion of solid cancer excess relative risk into lifetime attributable risk," Radiation and environmental biophysics, vol. 40, no. 4, pp. 249-257, 2001. [52]A. M. Kellerer, L. Walsh, and E. A. Nekolla, "Risk coefficient for γ-rays with regard to solid cancer," Radiation and environmental biophysics, vol. 41, no. 2, pp. 113-123, 2002. [53]L. Liao, S. Jiang, Y. Li et al., "TH‐C‐BRD‐12: Robust Intensity Modulated Proton Therapy Plan Can Eliminate Junction Shifts for Craniospinal Irradiation," Medical Physics, vol. 41, no. 6Part32, pp. 553-553, 2014. [54]A. Garcia, A. Locke, L. Smith et al., "Robust Planning Optimization Improves Safety and Homogeneity for Craniospinal Irradiation in the Supine Position," International Journal of Radiation Oncology, Biology, Physics, vol. 108, no. 3, pp. e346-e347, 2020. [55]A. Tasson, N. N. Laack, and C. Beltran, "Clinical implementation of robust optimization for craniospinal irradiation," Cancers, vol. 10, no. 1, p. 7, 2018. [56]L. Liao, G. J. Lim, Y. Li et al., "Robust optimization for intensity modulated proton therapy plans with multi-isocenter large fields," International journal of particle therapy, vol. 3, no. 2, pp. 305-311, 2016. [57]N. McVicar, "Improved volumetric modulated arc therapy field junctions using in silico base plans: application to craniospinal irradiation," Journal of medical imaging and radiation sciences, vol. 49, no. 3, pp. 301-308, 2018. [58]C. Demoor-Goldschmidt and F. de Vathaire, "Review of risk factors of secondary cancers among cancer survivors," The British journal of radiology, vol. 92, no. 1093, p. 20180390, 2019. [59]X. Mu, T. Björk-Eriksson, S. Nill et al., "Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study," Acta Oncologica, vol. 44, no. 6, pp. 554-562, 2005. [60]M. Tamura, H. Sakurai, M. Mizumoto et al., "Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients," Journal of radiation research, vol. 58, no. 3, pp. 363-371, 2017.
|